National Influenza and COVID-19 surveillance report
Week 9 report (up to week 8 2024 data)
29 February 2024
Contents

Contents............................................................................................................................................. 2
Executive summary.................................................................................................................................. 4
User feedback........................................................................................................................................ 6
Laboratory surveillance.......................................................................................................................... 7
  Respiratory DataMart system (England)............................................................................................... 7
  Confirmed COVID-19 cases (England)................................................................................................. 13
Microbiological surveillance.................................................................................................................. 16
  SARS-CoV-2 variants.......................................................................................................................... 16
  Influenza virus characterisation ........................................................................................................ 19
  Influenza antiviral susceptibility ......................................................................................................... 21
Community surveillance....................................................................................................................... 22
  SIREN healthcare cohort study ......................................................................................................... 22
  Winter COVID-19 Infection study ..................................................................................................... 23
  Acute respiratory infection incidents (ARI)......................................................................................... 25
FluSurvey ............................................................................................................................................... 28
Google search queries .......................................................................................................................... 30
Flu Detector .......................................................................................................................................... 31
Syndromic Surveillance ....................................................................................................................... 32
Primary care surveillance..................................................................................................................... 36
  RCGP Clinical Indicators (England).................................................................................................... 36
  RCGP sentinel swabbing scheme in England ..................................................................................... 37
Secondary care surveillance.................................................................................................................. 41
  Influenza, SARI Watch ...................................................................................................................... 41
  COVID-19, SARI Watch .................................................................................................................... 48
  ECMO, SARI Watch .......................................................................................................................... 53
  RSV admissions, SARI Watch ........................................................................................................... 54
Mortality surveillance.............................................................................................................................. 57
  COVID-19 deaths .............................................................................................................................. 57
  All-cause mortality assessment (England) ........................................................................................... 57
National Influenza and COVID-19 Report: week 9 report (up to week 8 2024 data)

Respiratory virus vaccination ........................................................................................................... 58
Influenza vaccination .......................................................................................................................... 58
COVID-19 vaccine uptake in England .................................................................................................. 58
International update .......................................................................................................................... 59
Global COVID-19 update .................................................................................................................... 59
Global influenza update ....................................................................................................................... 59
Other respiratory viruses .................................................................................................................... 59
Related links ........................................................................................................................................ 60
About the UK Health Security Agency ............................................................................................... 61

For additional information including regional data on COVID-19 and other respiratory viruses, COVID-19 in educational settings, co- and secondary infections with COVID-19 and other data supplementary to this report, please refer to the accompanying graph pack.

For additional information regarding data source please refer to Sources of surveillance data for influenza, COVID-19 and other respiratory viruses.
Executive summary

This report summarises the information from the surveillance systems which are used to monitor COVID-19 (caused by SARS-CoV-2), influenza, and diseases caused by seasonal respiratory viruses in England. References to COVID-19 represent the disease name and SARS-CoV-2 represent the virus name. The report is based on data from week 8 2024 (between 19 February and 25 February 2024).

Overall

In week 8, influenza and COVID-19 activity continued to decrease across most indicators. Respiratory syncytial virus (RSV) activity remained low with indications of further decreases across some indicators.

Influenza

Through Respiratory DataMart, influenza positivity decreased to 7.4% in week 8 compared to 10.2% in the previous week.

Through primary care surveillance, the influenza-like-illness (ILI) consultations indicator decreased to 6.7 per 100,000 in week 8 compared to 7.6 per 100,000 in the previous week and remained within the baseline activity level range. The influenza positivity in GP sentinel swabbing decreased in week 7 compared to week 6.

Through SARS-CoV-2 Immunity and Reinfection Evaluation (SIREN) healthcare worker cohort study, the influenza positivity decreased in week 8 compared to the previous week.

There were 29 confirmed influenza acute respiratory incidents (ARI) reported in week 8. This number remained stable compared to the previous week.

Overall, influenza hospitalisations decreased to 3.14 per 100,000 in week 8 compared to 4.26 per 100,000 in the previous week and decreased to the low impact range. The overall intensive care unit (ICU) or high dependency unit (HDU) admission rate remained stable at 0.09 per 100,000, the same as in the previous week and was within the baseline impact range.

Emergency department (ED) attendances for ILI decreased overall.

COVID-19

Through Respiratory DataMart, SARS-CoV-2 positivity decreased to 4.3% in week 8 compared to 5.0% in the previous week.

COVID-19 case rates and positivity in Pillar 1 decreased overall and within most ethnic groups and regions, and all age groups in week 8.
The overall number of reported SARS-CoV-2 confirmed acute respiratory incidents in week 8 remained stable compared to the previous week. There were 9 SARS-CoV-2 confirmed acute respiratory incidents reported in week 8 in England.

Winter Coronavirus (COVID-19) Infection Study (CIS) estimated community prevalence of COVID-19 decreased to 0.9% (95% CrI: 0.6% to 1.2%), equating to 525,000 (95% CrI: 381,000 to 717,000) people infected in England and Scotland overall and around 44,100 (95% CrI: 27,200 to 69,400) new SARS-CoV-2 infections each day.

Through SIREN healthcare cohort study, the SARS-CoV-2 positivity decreased in week 8 compared to the previous week.

Overall, COVID-19 hospitalisations decreased to 2.23 per 100,000 in week 8 compared to 2.98 per 100,000 in the previous week. Hospitalisations were highest in the 85 years and over age group. COVID-19 ICU admissions remained low and remained stable at 0.09 per 100,000 in week 8.

**Respiratory Syncytial Virus (RSV)**

Through Respiratory DataMart, positivity for RSV remained low at 0.8%, with the highest positivity in those aged under 5 years at 1.8%. ED attendances for acute bronchiolitis remained stable nationally. Through SIREN healthcare cohort study, the RSV positivity increased slightly in week 8 compared to the previous week. Overall RSV hospitalisations decreased to 0.19 per 100,000, compared to 0.36 per 100,000 in the previous week.

**Other viruses**

Adenovirus positivity remained low at 2.5%, with the highest positivity in those aged under 5 years at 7.2%. Human metapneumovirus (hMPV) positivity increased slightly to 3.5%, with the highest positivity in those aged under 5 years at 8.2%. Parainfluenza positivity decreased slightly to 3.3%, with the highest positivity in those aged under 5 years at 9.6%. Rhinovirus positivity decreased slightly to 6.8% overall, with the highest positivity in those aged under 5 years at 20.4%.
User feedback

As part of our ongoing commitment to continuous improvement, we are asking for feedback on the National weekly influenza and COVID-19 surveillance report through the survey accessible below. The purpose of this survey is to deepen our understanding of how readers engage with the report, highlighting areas readers find valuable and pinpointing areas for enhancement. The insights obtained from this survey will play a pivotal role in shaping the direction of future report development. The survey will be open until the end of the weekly reporting season.

Scan this QR code using a mobile device:
Laboratory surveillance

Respiratory DataMart system (England)

In week 8, data is based on reporting from 12 out of the 16 sentinel laboratories.

In week 8, 6,143 respiratory specimens reported through the Respiratory DataMart System were tested for influenza. There were 454 positive samples for influenza; 272 influenza A(not subtyped), 121 influenza A(H3N2), 22 influenza A(H1N1)pdm09, and 39 influenza B (Figure 3). Overall, influenza positivity decreased to 7.4% in week 8 compared to 10.2% in the previous week.

In week 8, 5,665 respiratory specimens reported through the Respiratory DataMart System were tested for SARS-CoV-2. There were 242 positive samples for SARS-CoV-2 with an overall positivity of 4.3%, which decreased compared to 5.0% in the previous week. The highest positivity was seen in adults aged over 65 years at 6.3%.

RSV positivity remained low at 0.8%, with the highest positivity in those aged under 5 years at 1.8%.

Adenovirus positivity remained low at 2.5%, with the highest positivity in those aged under 5 years at 7.2%.

Human metapneumovirus (hMPV) positivity increased slightly to 3.5%, with the highest positivity in those aged under 5 years at 8.2%.

Parainfluenza positivity decreased slightly to 3.3%, with the highest positivity in those aged under 5 years at 9.6%.

Rhinovirus positivity decreased slightly to 6.8% overall, with the highest positivity in those aged under 5 years at 20.4%.

DataMart data is provisional and subject to retrospective updates.
Figure 1a. Respiratory DataMart weekly positivity (%) for influenza, SARS-CoV-2, RSV and rhinovirus, England

Figure 1b. Respiratory DataMart weekly positivity (%) for adenovirus, hMPV and parainfluenza, England
Figure 2. Respiratory DataMart weekly positivity (%) for influenza by year, England [note 1]

[note 1] Data from seasons 2020 to 2021 and 2021 to 2022 has been removed as there was low activity throughout these seasons.

Figure 3. Respiratory DataMart samples positive for influenza by type and subtype, England
Figure 4. Respiratory DataMart weekly positivity (%) for influenza by age, England
Figure 5. Respiratory DataMart weekly positivity (%) for SARS-CoV-2 by year, England

Figure 6. Respiratory DataMart weekly positivity (%) for SARS-CoV-2 by age, England
Figure 7. Respiratory DataMart weekly positivity (%) for RSV by year, England

Figure 8. Respiratory DataMart weekly positivity (%) for RSV by age, England
Confirmed COVID-19 cases (England)

As of 9am on 27 February 2024, there were a total of 1,363 Pillar 1 cases in week 8, a 30.5% decrease from the previous week.

COVID-19 polymerase chain reaction (PCR) positivity for Pillar 1 decreased in week 8, with a weekly mean positivity rate of 5.8% compared to 6.7% in the previous week. Pillar 1 positivity rates were highest in those aged 85 years and over group at a weekly mean positivity rate of 10.4% (decreased slightly from 11.0% among those aged 85 years and over in week 7) and in Yorkshire and Humber at a weekly mean positivity rate of 7.0% (decreased from 7.3% in week 7).

Data notes: Changes to testing policies over time may affect positivity rates and incidence rates and should be interpreted accordingly. COVID-19 case reporting in England uses an episode-based definition which includes possible reinfections, each infection episode is counted separately if there are at least 91 days between positive test results (PCR or rapid lateral flow device). Each infection episode begins with the earliest positive specimen date. Additionally, further changes in testing policy are in effect since 1 April 2023, which may affect case rates and positivity rates.

Figure 9. Confirmed COVID-19 episodes tested under Pillar 1, based on sample date with overall 7-day rolling average PCR positivity for Pillar 1 (%) [note 2]

[note 2] The vertical dashed line (red) denotes changes in testing policies.
Age

Figure 10. 7-day rolling average PCR positivity (%) of confirmed COVID-19 cases tested under Pillar 1 by age group [note 3]

[note 3] The highlighted line corresponds to the age group in the subplot title, grey lines correspond to all other age groups.

Geography

Figure 11. 7-day rolling average PCR positivity (%) of confirmed COVID-19 cases tested under Pillar 1 by UKHSA region [note 4]

[note 4] The highlighted line corresponds to the UKHSA region in the subplot title, grey lines correspond to all other regions.
Ethnicity

Figure 12: Weekly incidence of confirmed COVID-19 cases per 100,000 population by ethnicity (Pillar 1), England [note 5]

[note 5] The highlighted line corresponds to the ethnicity in the subplot title, grey lines correspond to all other ethnicities.
Microbiological surveillance

SARS-CoV-2 variants

This section is updated fortnightly. There is an update in this report.

The UK Health Security Agency (UKHSA) conducts genomic surveillance of SARS-CoV-2 variants.

This section provides an overview of new and current circulating variants in England.

Detailed information on circulating SARS-CoV-2 lineages is published monthly and can be found in the SARS-CoV-2 genome sequence prevalence and growth rate updates.

Information on whole genome sequencing coverage of PCR tests can be found in the accompanying slide set.

The sequence data used in this report is classified using UKHSA variant definitions (rather than Pangolin lineage assignment, which is commonly used to assign lineages to sequences). UKHSA defines variants based on a set of mutations common to a lineage to allow consistent detection, monitoring and reporting.

Poorer quality sequence data may be classified as a more ancestral variant due to missing data. Furthermore, variants may include sub-lineages that have not been individually designated for example HK.3 within EG.5.1 (V-23JUL-01). Once a sub-lineage meets required thresholds, it will be designated as a variant and prevalence of this sub-lineage in positive cases will then be identifiable in the data. The UKHSA variant definition repository contains the previous genomic definitions for UKHSA declared variants.

The prevalence of different UKHSA-designated variants amongst sequenced cases is presented in Figure 13.

To account for sequencing delays, we report the proportion of variants from sequenced cases between 5 February 2024 and 11 February 2024. Of those sequenced in this period, 85.5% were classified as JN.1 (V-23DEC-01), 6.2% as BA.2.86 (V-23AUG-01), 3.7% as BA.2 (V-22JAN-01), 1.9% as EG.5.1 (V-23JUL-01) and 1.8% as XBB (V-22OCT-02).
The grey line indicates proportion of cases sequenced. The vertical dashed line (red) in April 2023 denotes changes in PCR testing in social care and hospital settings.

[note 6] Recombinants such as XD, are not specified but are largely within the ‘Other’ group currently as numbers are too small.
Table 1. Total distribution of SARS-CoV-2 variants detected in England in the last 12 weeks, up to week 7 (week ending 18 February 2024) [note 7]

<table>
<thead>
<tr>
<th>Variant</th>
<th>Other names by which this variant is known</th>
<th>Total sequenced cases in the last 12 weeks [note 7]</th>
<th>Last reported specimen date</th>
</tr>
</thead>
<tbody>
<tr>
<td>V-23DEC-01</td>
<td>Omicron JN.1</td>
<td>8,376</td>
<td>18-02-2024</td>
</tr>
<tr>
<td>V-23AUG-01</td>
<td>Omicron BA.2.86</td>
<td>1,767</td>
<td>18-02-2024</td>
</tr>
<tr>
<td>V-23JUL-01</td>
<td>Omicron EG.5.1</td>
<td>1,081</td>
<td>15-02-2024</td>
</tr>
<tr>
<td>V-22OCT-02</td>
<td>Omicron XBB</td>
<td>831</td>
<td>17-02-2024</td>
</tr>
<tr>
<td>V-23JAN-01</td>
<td>Omicron XBB.1.5</td>
<td>294</td>
<td>16-02-2024</td>
</tr>
<tr>
<td>V-22JAN-01</td>
<td>Omicron BA.2</td>
<td>249</td>
<td>18-02-2024</td>
</tr>
<tr>
<td>V-23APR-01</td>
<td>Omicron XBB.1.16</td>
<td>191</td>
<td>03-02-2024</td>
</tr>
</tbody>
</table>

[note 7] Sequenced cases are PCR confirmed COVID-19 cases with a validated sequencing result meeting the case definitions.

Designated variants with 50 or more sequenced cases in the past 12 weeks are presented in the table above.

Sequencing data has a lag of approximately 2 weeks therefore the data presented should be interpreted in this context.

Cumulative numbers may be revised up or down as a result of reclassification, re-infections and changes to diagnostic tests, new variants or public health management levels.
Influenza virus characterisation

UKHSA characterises the properties of influenza viruses through one or more tests, including genome sequencing (genetic analysis) and haemagglutination inhibition (HI) assays (antigenic analysis). These data are used to compare how similar the currently circulating influenza viruses are to the strains included in seasonal influenza vaccines, and to monitor for changes in circulating influenza viruses. The interpretation of genetic and antigenic data sources is complex due to a number of factors, for example, not all viruses can be cultivated in sufficient quantity for antigenic characterisation, so that viruses with sequence information may not be able to be antigenically characterised as well. Occasionally, this can lead to a biased view of the properties of circulating viruses, as the viruses which can be recovered and analysed antigenically, may not be fully representative of majority variants, and genetic characterisation data does not always predict the antigenic characterisation.

As of week 8 of 2024, the UKHSA Respiratory Virus Unit (RVU) has genetically characterised 767 influenza A(H3N2) viruses, which had been detected this season (since week 40), with 765 of these belonging in genetic subclade 3C.2a1b.2a.2 in the 2a.3a.1 subgroup. Two A(H3N2) viruses belonging to subgroup 2a.3 were characterised. The Northern Hemisphere 2023/24 influenza A(H3N2) vaccine strain (an A/Darwin/9/2021-like virus) also belongs in genetic subclade 3C.2a1b.2a.2.

In the same period, 898 influenza A(H1N1)pdm09 viruses have been characterised. Sequencing of the haemagglutinin (HA) gene shows that 758 belong in genetic subgroup 6B.1A.5a.2a and 140 in subgroup 6B.1A.5a.2a.1. The Northern Hemisphere 2023/24 influenza A(H1N1)pdm09 vaccine strain (an A/Victoria/4897/2022 (H1N1)pdm09-like virus) also belongs in genetic subclade 6B.1A.5a, within the 6B.1A.5a.2a.1 cluster.

Since week 40, 120 influenza B/Victoria lineage viruses have been genetically characterised belonging in clade V1A.3a.2. Of these, 119 viruses belonging in genetic subclade C.5 and one in C.2. The Northern Hemisphere 2023/24 influenza B/Victoria lineage vaccine strain (a B/Austria/1359417/2021-like virus) also belongs in this V1A.3a.2 clade.

Different lineages may dominate during the season, and a close watch will be kept on the proportion of different viruses circulating to assist with the evaluation of vaccine effectiveness.

The RVU has confirmed by genome sequencing the detection of live attenuated influenza vaccine (LAIV) viruses in 5 influenza A positive samples and in 8 influenza B positive samples collected since week 40, from children aged between 2 and 16 years.

One influenza A(H1N2)v virus has been genetically characterised belonging in clade 1B 1.1. This is an unusual detection of a variant H1N2 (H1N2v) virus in a human clinical sample. The HA and NA genes as well as internal gene segments from the A(H1N2)v detection show a very close relationship to contemporary 1B.1.1 swine influenza A viruses from the UK.
Table 2. Number of influenza viruses characterised by genetic and antigenic analysis at the UKHSA Respiratory Virus Unit since week 40 of 2023

<table>
<thead>
<tr>
<th>(Sub)type</th>
<th>Genetic group</th>
<th>Number sequenced</th>
</tr>
</thead>
<tbody>
<tr>
<td>A(H3N2)</td>
<td>3C.2a1b.2a.2a.3a.1</td>
<td>765</td>
</tr>
<tr>
<td></td>
<td>3C.2a1b.2a.2a.3</td>
<td>2</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>767</td>
</tr>
<tr>
<td>A(H1N1)pdm09</td>
<td>6B.1A.5a.2a</td>
<td>758</td>
</tr>
<tr>
<td></td>
<td>6B.1A.5a.2a.1</td>
<td>140</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>898</td>
</tr>
<tr>
<td>B/Victoria-lineage</td>
<td>V1A3a.2 / C.5</td>
<td>119</td>
</tr>
<tr>
<td></td>
<td>V1A3a.2 / C.2</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>120</td>
</tr>
<tr>
<td>A(H1N2)v</td>
<td>1B.1.1</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>1</td>
</tr>
</tbody>
</table>
Influenza antiviral susceptibility

Influenza positive samples are genome sequenced and screened for mutations in the virus neuraminidase (NA) and the cap-dependent endonuclease (PA) genes known to confer neuraminidase inhibitor or baloxavir resistance, respectively. The samples tested are routinely obtained for surveillance purposes, but diagnostic testing of patients suspected to be infected with antiviral-resistant virus is also performed.

Influenza virus sequences from samples collected between week 40 of 2023 and week 8 of 2024 have been analysed.

Analysis of 746 A(H3N2) viruses found no viruses with known markers of resistance to neuraminidase inhibitors. Analysis of 896 A(H1N1)pdm09 by sequencing found 5 oseltamivir resistant viruses taken from 4 patients:

- Patient 1: 2 samples with a H275Y amino acid substitution. Immune compromised adult patient known to have received oseltamivir treatment.
- Patient 2: one sample with a H275Y amino acid substitution. Adult patient with a COPD exacerbation known to have received oseltamivir treatment.
- Patient 3: one sample with a H275Y amino acid substitution. Immune compromised adult patient known to have received oseltamivir treatment.
- Patient 4: one sample with a D199E amino acid substitution. Immune compromised adult patient known to have received oseltamivir treatment.

Analysis of 118 influenza B NA sequences found no evidence of known markers of resistance to neuraminidase inhibitors.

No viruses with known markers of resistance to baloxavir marboxil were detected in 666 A(H3N2), 743 A(H1N1)pdm09 and 104 influenza B PA sequences analysed.

Table 3. Antiviral susceptibility of influenza positive samples tested at UKHSA-RVU

<table>
<thead>
<tr>
<th>(Sub)type</th>
<th>Neuraminidase inhibitors: susceptible</th>
<th>Neuraminidase inhibitors: reduced susceptibility</th>
<th>Baloxavir: susceptible</th>
<th>Baloxavir: reduced susceptibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>A(H3N2)</td>
<td>746</td>
<td>0</td>
<td>666</td>
<td>0</td>
</tr>
<tr>
<td>A(H1N1)pdm09</td>
<td>891</td>
<td>5</td>
<td>743</td>
<td>0</td>
</tr>
<tr>
<td>B/Victoria-lineage</td>
<td>118</td>
<td>0</td>
<td>104</td>
<td>0</td>
</tr>
</tbody>
</table>
Community surveillance

SIREN healthcare cohort study

This section is now updated weekly with updated data presented in this report.

The SIREN healthcare cohort study was set up in June 2020 and recruited over 44,500 participants to investigate SARS-CoV-2 infections and immunity among UK healthcare workers. 6,000 participants from the original cohort were re-recruited into the study and undergo fortnightly asymptomatic PCR testing for SARS-CoV-2, influenza A/B and RSV, to monitor positivity rates and the emergence of new SARS-CoV-2 variants. Participants are distributed across the UK, with a median age of 53 years, and 78% are female.

Please note: SIREN participants are currently divided into 2 cohorts that test fortnightly, on alternate weeks. The SIREN study team used a targeted recruitment strategy for the second cohort, to increase the numbers of under-represented groups within the study. Therefore, the demographic breakdown of each cohort differs slightly.

Figure 14 describes weekly positivity rates (per 100 tests) of SARS-CoV-2, Influenza A/B and RSV in the SIREN cohort over the last 12 months. During the week commencing 19 February 2024, 1,425 swabs were tested (49.7% of participants). Influenza positivity decreased compared to the previous week (0.84% positive compared to 1.15%). SARS-CoV-2 positivity decreased in the previous week (0.99% positive compared to 1.10%). RSV positivity increased in the previous week (0.28% positive compared to 0.16%).

Figure 14. SIREN study weekly PCR positivity (%) for influenza, SARS-CoV-2 and RSV, UK
Winter COVID-19 Infection study

This section is updated fortnightly. There is updated data presented in this report. The Winter Coronavirus (COVID-19) Infection Study aims to understand the impact of COVID-19, particularly over the winter period. The study is run jointly by the Office for National Statistics (ONS) and UKHSA, with data collected via online questionnaire completion and self-reported lateral flow device (LFD) results from previous participants of the COVID-19 Infection Survey.

Modelled prevalence & incidence
Prevalence is a modelled estimate of people currently infected with SARS-CoV-2 using percentage of people testing positive (percentage of people infected with SARS-CoV-2) and adjusted to account for lower sensitivity of LFD tests and weighted to be representative of the general population. This week, UKHSA is releasing modelled estimates of daily incidence, which is a measure of new infections occurring over a chosen time period. These estimates are published by UKHSA (Winter COVID-19 Infection Study) and are presented as daily estimates.

On 21 February 2024, the estimated prevalence in England and Scotland was 0.9% (95% credible interval (CrI): 0.6% to 1.2%) compared to 1.2% (95% CrI 1.0% to 1.5%) on 14 February 2024 (figure 15). The estimated prevalence on 21 February 2024 corresponds to around 525,000 (95% CrI 381,000 to 717,000) people infected or 1 in 111 people (95% CrI: 1 in 167 to 1 in 83). Graphs on prevalence by age and region are shown in the supplementary slide set.

In England and Scotland, the estimated incidence rate of SARS-CoV-2 per 100,000 individuals on 18 February 2024 was 74 (95% CrI: 45 to 116) which is equivalent to around 44,100 (95% CrI: 27,200 to 69,400) individuals newly infected with SARS-CoV-2 per day. Further breakdowns of incidence are presented in the main publication by UKHSA.

Figure 15. Estimates of prevalence between 14 November 2023 and 21 February 2024, Winter CIS, England and Scotland
Percentage testing positive

This section presents the number of people who self-reported a positive LFD result out of those who self-reported an LFD test result in England, as reported by ONS (Winter Coronavirus (COVID-19) Infection Study, England and Scotland). The results are presented by reporting week. Results are weighted to be representative of the population of England.

In the latest week, weighted positivity was 0.8% (95% confidence interval 0.6%-1.1%) between 15 February 2024 and 21 February 2024 and 1.3% (95% confidence interval 0.9%-1.6%) between 8 February 2024 and 14 February 2024 (Figure 16).

The age group with the highest weighted positivity in the latest week were in those aged between 18 and 34 years (1.2%, 95% CI of 0.3% to 2.1%). In the latest week, South West was the region with the highest positivity (1.3%, 95% CI of 0.2% to 2.3%). Data on age and region can be found in the supplementary data file.

Figure 16. Percentage testing positive for COVID-19, Winter COVID-19 infection study, England
Acute respiratory infection incidents (ARI)

Here we present data on ARI incidents in different settings that are reported to UKHSA Health Protection Teams (HPTs).

There were 58 new ARI incidents reported in week 8 in England. In the latest week, these included:

- 54 incidents reported from care homes, of which 26 were laboratory confirmed for influenza A(not subtyped), 7 for SARS-CoV-2 and 1 for RSV.
- 2 incidents reported from hospitals, of which one were laboratory confirmed for influenza A(not subtyped) and 1 for SARS-CoV-2
- No incidents reported from educational settings
- one incident reported from a prison, with a mixed infection of SARS-CoV-2 and influenza (no subtype information available)
- one incident reported from an other setting with an influenza A(not subtyped) infection

Please note that data back to week 40 was retrospectively updated following an improvement in the method to assign incidents to an identified pathogen using reports from health protection teams.
Figure 17. Number of ARI incidents by setting, England

Figure 18. Number of ARI incidents in all settings by virus type, England
Figure 19. Number of ARI incidents in care homes by virus type, England

Figure 20. Number of ARI incidents in educational settings by virus type, England
FluSurvey

FluSurvey is an internet-based participatory surveillance system based on the InfluenzaNet platform. FluSurvey monitors trends of influenza-like illness (ILI) in the community using self-reported respiratory symptoms from registered participants. The platform has been adapted to capture respiratory symptoms, exposure risk and healthcare seeking behaviours among registered participants to contribute to national surveillance of COVID-19 activity as well as influenza activity since week 44 of 2020.

The survey had a planned pause in summer 2023 (as was the norm prior to COVID-19 emergence) and restarted in autumn 2023 on the FluSurvey 2.0 web platform with a mixture of previous participants and new participants. Therefore, the baseline demographics and level of symptoms may have changed compared to last season, including the possibility that new registrations and re-registrations may have been initiated by recent onset of illness.

Note that ILI is defined as sudden onset of symptoms with at least one of fever (chills), malaise, headache, muscle pain and at least one of cough, sore throat, shortness of breath.

During week 8, there were 1,686 participants completing the weekly symptoms questionnaire of which 149 (8.8%) reported fever or cough and 44 (2.6%) reported ILI. Both COVID-19 like symptoms and influenza-like-illness decreased amongst participants reporting symptoms in week 8. The most commonly reported contact with healthcare services as a result of symptoms was a visit to a GP surgery.

Healthcare use is presented as total use due to reported related symptoms and is classified by the most resource intensive use of health care resource if any is used (hospital being more intensive than physically visiting the general practitioner). Amongst people reporting at least one respiratory symptom, the most reported contact with healthcare services was a visit to their GP surgery.

Self-reported daily social contact patterns by participants reporting symptoms are also reported. A contact is defined as a person outside the household who is approached at less than one metre, on the day prior to survey completion (Figure 22). There remains variation on social mixing patterns amongst participants with more people reporting not meeting any individual outside of their households during week 8.
Figure 21. FluSurvey participants self-reporting fever or cough and ILI symptoms, and trends in healthcare seeking behaviour among these participants, England [note 8]

[note 8] Please note in week 49 of 2022 there was no data available. The lines in the upper panel have been continued using interpolation.

Figure 22. FluSurvey participants’ self-reported number of social contacts outside the household
Google search queries

This is a web-based syndromic surveillance system which uses daily search query frequency statistics obtained from the Google Health Trends API (Application Programming Interface). This model focuses on search queries about COVID-19 symptoms as well as generic queries about ‘coronavirus’ (for example ‘COVID-19’). The search query frequency time series is weighted based on symptom frequency as reported in other data sources. Frequency of searches for symptoms is compared with a baseline calculated from historical daily data. Further information on this model is available online.

During week 8, the overall and media-debiasing weighted Google search scores decreased compared to the previous week (Figure 23).

Figure 23. Normalised Google search score for COVID-19 symptoms, with weighted score for media-debiasing and historical trend, England
Flu Detector

FluDetector is a web-based model which assesses internet-based search queries for influenza-like illness (ILI) in the general population.

Daily ILI rate estimates are based on uniformly averaged search query frequencies for a week-long period (including the current day and the 6 days before it).

For week 8, the daily ILI query rate decreased and activity remained below baseline activity (Figure 24).

Figure 24. Daily estimated ILI Google search query rates per 100,000 population, England
Syndromic Surveillance

During week 8, NHS 111 calls for cold or flu decreased overall. NHS 111 calls for cough also decreased. GP in-hours consultation rates for influenza-like-illness (ILI) decreased nationally. GP out of hours contacts for acute respiratory infection decreased, however contacts for influenza-like-illness increased nationally during week 8. ED attendances for acute respiratory infections and ILI decreased nationally. ED attendances for acute bronchiolitis remained stable.

For further information on syndromic surveillance please see the Syndromic Surveillance: weekly summaries.
Figure 25a. Daily ED attendances for acute respiratory infection nationally, England [note 9]

[note 9] The solid black line is a 7-day moving average adjusted for holidays. The solid green line is the daily attendances. The black dotted line is the baseline. The grey columns show weekends and bank holidays.

Figure 25b. Daily ED attendances for acute respiratory infection by age group, England [note 10]

[note 10] The scales may vary in each graph to enable trend comparison. The black line is the 7-day moving average adjusted for bank holidays.
Figure 26a. Daily ED attendances for influenza-like illness nationally, England [note 9]

See [note 9] as above.

Figure 26b. Daily ED attendances for influenza-like illness by age group, England [note 10]

See [note 10] as above.
Figure 27a. Daily ED attendances for acute bronchiolitis nationally, England [note 11]

See [note 9] as above.

Figure 27b. Daily ED attendances for acute bronchiolitis by age group, England [note 12]

See [note 10] as above.

[note 11] Please note, there was no update in week 14 for acute bronchiolitis syndromic surveillance.
Primary care surveillance

RCGP Clinical Indicators (England)

The weekly ILI consultation rate through the Royal College of General Practitioners (RCGP) surveillance decreased to 6.7 per 100,000 registered population in participating GP practices in week 8 compared to 7.6 per 100,000 in the previous week. This was within baseline activity levels (less than 10.25 per 100,000) (Figure 28). By age group, the highest rates were seen in those aged under 1 year (10.1 per 100,000), followed by those aged between 15 and 44 years (7.3 per 100,000). The lower respiratory tract infections (LRTI) consultation rate remained stable at 115.6 per 100,000 in week 8 compared to 117.2 per 100,000 in the previous week.

Figure 28. RCGP ILI consultation rates, all ages, England

Moving Epidemic Method (MEM) thresholds are based on data from the 2015 to 2016 season to the 2022 to 2023 season. Please note the 2020 to 2021 and 2021 to 2022 seasons have been removed due to low activity throughout these seasons.
RCGP sentinel swabbing scheme in England

Due to reporting delays, there were insufficient results of samples taken in week 8 of 2024 to report. These will be included in next week’s report. Additionally, starting in week 51, testing for enterovirus and rhinovirus have been delayed.

Based on the date samples were taken, in week 7 of 2024 (week commencing 12 February 2024) 706 samples were tested through the GP sentinel swabbing scheme in England of which 57 samples tested positive (Figure 29). Among all positive samples, 43.9% were positive for influenza, 26.3% were positive for other seasonal coronaviruses, 19.3% were positive for hMPV, 5.3% were positive for SARS-CoV-2, 3.5% were positive for RSV and 1.7% were positive for adenovirus (Figure 30). Due to the number of samples which have not yet been categorised, data should be interpreted with caution when compared to previous weeks. There was a result for one sample in week 8. The proportion of detections among all positive samples is not calculated when the number of samples with result is less than 50.

Among all samples which had a known test result, in week 7, positivity for SARS-CoV-2 was 1.1%, positivity for influenza was 10.2%, and positivity for RSV was 0.8% (Figure 31). Due to the number of samples which have not yet been categorised, data should be interpreted with caution when compared to previous weeks.

In previous reports, figure 27 and figure 28 were produced based on the date samples were received in the reference laboratory. From 23 November 2023 (week 47 report) these figures have been updated to be based on the date samples were taken.

From 27 November 2023, swabbing was temporarily increased in the Yorkshire and Humber region in response to the identification of a case of influenza A(H1N2)v. This may lead to an over-representation of the Yorkshire and Humber region.
Figure 29. Number of samples tested for SARS-CoV-2, influenza, and other respiratory viruses in England by week, GP sentinel swabbing [note 12]

[note 12] Unknown category corresponds to samples with no result yet.
Figure 30. Proportion of detections of SARS-CoV-2, influenza, and other respiratory viral strains amongst virologically positive respiratory surveillance samples in England by week, GP sentinel swabbing scheme [note 13] [note 14]

[From week 51 data contains a substantial reduction of test results for enterovirus and rhinovirus due to a delay in testing for these pathogens.]
[Data from the most recent weeks are not shown on this graph due to reporting delays.]
Figure 31. Weekly positivity (%) for COVID-19, influenza and RSV in England, GP sentinel swabbing [note 14]

See [note 14] as above.
Secondary care surveillance

Influenza, SARI Watch

Surveillance of influenza hospitalisations to all levels of care is based on data from a small sentinel network of acute NHS trusts in England. Surveillance of admissions to ICU or HDU for influenza is mandatory with data required from all acute NHS trusts in England. Please note that the SARI Watch rates for 2023 to 2024 use the latest trust catchment population. For consistency the rates have been updated back to October 2020. The population denominator reflects changes in trust reconfiguration, hospital admission activity and population estimates.

In week 8 (ending 25 February 2024), the overall weekly hospital admission rate for influenza decreased to 3.14 per 100,000 compared to 4.26 per 100,000 in the previous week. The latest rate crossed into the low impact range (1.57 to 3.91 per 100,000). There were 316 new hospital admissions for influenza (237 influenza A(not subtyped), 28 influenza A(H1N1)pdm09, 21 influenza A(H3N2), and 30 influenza B).

In week 8, the overall ICU or HDU rate for influenza remained stable at 0.09 per 100,000, the same as the previous week. The rate in the latest week remained within the baseline impact range (less than 0.11 per 100,000). There were 39 new case reports of an ICU or HDU admission for influenza in week 8 (28 influenza A(not subtyped), 4 influenza A(H1N1)pdm09, 2 influenza A(H3N2), and 5 influenza B).
Figure 32. Weekly overall influenza hospital admission rates per 100,000 trust catchment population with MEM thresholds, reported through SARI Watch sentinel surveillance, England

MEM thresholds are based on data from the 2015 to 2016 season to the 2022 to 2023 season. Please note the 2020 to 2021 and 2021 to 2022 seasons have been removed due to low activity throughout these seasons. Influenza hospital admission rate based on 25 sentinel NHS trusts for week 8. SARI Watch data is provisional and subject to retrospective updates.
Figure 33. Weekly influenza hospital admissions by influenza type, reported through SARI Watch sentinel surveillance, England [note 15]

[note 15] Number of influenza hospital admissions based on sentinel NHS trusts

Figure 34. Weekly hospital admission rate by UKHSA region for new influenza reported through SARI Watch sentinel surveillance [note 4] [note 16]

[note 16] Rates in some regions may not include all influenza surveillance sentinel trust sites from week to week. This may lead to variation in regional representation hence caution is required in interpreting the weekly data by region.

See [note 4] as above.
Figure 35a. Weekly hospital admission rate by age group for new influenza reported through SARI Watch sentinel surveillance - fixed y-axis [note 3]

See [note 3] as above.

Figure 35b. Weekly hospital admission rate by age group for new influenza reported through SARI Watch sentinel surveillance - adjusted y-axis
Figure 36. Weekly overall influenza ICU or HDU admission rates per 100,000 trust catchment population with MEM thresholds, reported through SARI Watch mandatory surveillance, England

MEM thresholds are based on data from the 2015 to 2016 to the 2022 to 2023 seasons. Please note the 2020 to 2021 and 2021 to 2022 seasons have been removed due to low activity throughout these seasons.

Influenza ICU or HDU admission rate based on 99 NHS trusts for week 8.
SARI Watch data is provisional and subject to retrospective updates.
Figure 37. Weekly influenza ICU or HDU admissions by influenza type, reported through SARI Watch mandatory surveillance, England

Figure 38. Weekly ICU or HDU admission rate by UKHSA region for new influenza, reported through SARI Watch mandatory surveillance [note 4]

See [note 4] as above
Figure 39a. Weekly ICU or HDU admission rate by age group for new influenza cases, reported through SARI Watch mandatory surveillance - fixed y-axis [note 3]

See [note 3] as above.

Figure 39b. Weekly ICU or HDU admission rate by age group for new influenza cases, reported through SARI Watch mandatory surveillance - adjusted y-axis
COVID-19, SARI Watch

Surveillance of COVID-19 hospitalisations to all levels of care and surveillance of admissions to ICU or HDU for COVID-19 are both mandatory with data required from all acute NHS trusts in England. Please note that the SARI Watch rates for 2023 to 2024 use the latest trust catchment population. For consistency the rates have been updated back to October 2020.

In week 8 (ending 25 February 2024), the overall weekly hospital admission rate for COVID-19 decreased to 2.23 per 100,000 compared to 2.98 per 100,000 in the previous week. By UKHSA region, the highest hospital admission rate for COVID-19 was observed in the South West (decreased to 2.65 per 100,000 from 3.68 per 100,000 in the previous week, all other regions decreased). By age group, the highest hospital admission rate for confirmed COVID-19 continued to be in those aged 85 years and over but decreased further to 27.12 per 100,000, all other age groups decreased or remained stable.

In week 8 (ending 25 February 2024), the overall weekly ICU or HDU admission rate for COVID-19 was very low and remained stable at 0.09 per 100,000, the same as the previous week. Note that with very low rates in critical care, small random fluctuations may occur. Note that ICU or HDU admission rates may represent a lag from admission to hospital to an ICU or HDU ward. The ICU or HDU admission rate for COVID-19 by UKHSA centre or by age group is currently fluctuating at low levels due to low underlying numbers.

Figure 40a. Weekly overall COVID-19 hospital admission rates per 100,000 trust catchment population, reported through SARI Watch mandatory surveillance, England

COVID-19 hospital admission rate based on 90 NHS trusts for week 8. SARI Watch data is provisional and subject to retrospective updates.
Figure 40b. Weekly percentage of hospitalisations with COVID-19 as primary reason, reported through SARI Watch sentinel surveillance, England

Data on proportions of hospitalisations primarily due to COVID is based on returns from a smaller number of participating trusts in sentinel surveillance and may not be representative of all acute NHS trusts

Figure 41. Weekly hospital admission rate by UKHSA region for new COVID-19 positive cases, reported through SARI Watch mandatory surveillance [note 4]

See [note 4] as above.
Figure 42a. Weekly hospital admission rate by age group for new COVID-19 positive cases reported through SARI Watch mandatory surveillance - fixed y-axis [note 3]

See [note 3] as above.

Figure 42b. Weekly hospital admission rate by age group for new COVID-19 positive cases reported through SARI Watch mandatory surveillance - adjusted y-axis
COVID-19 ICU or HDU admission rate based on 75 NHS trusts for week 8. SARI Watch data is provisional and subject to retrospective updates.

Figure 44: Weekly ICU or HDU admission rate by UKHSA region for new COVID-19 positive cases reported through SARI Watch mandatory surveillance [note 4]

See [note 4] as above.
Figure 45a. Weekly ICU or HDU admission rate by age group for new COVID-19 positive cases reported through SARI Watch mandatory surveillance - fixed y-axis [note 3]

See [note 3] as above.

Figure 45b. Weekly ICU or HDU admission rate by age group for new COVID-19 positive cases reported through SARI Watch mandatory surveillance adjusted y-axis
ECMO, SARI Watch

There were 3 new extra corporeal membrane oxygenation (ECMO) admissions reported in week 8 from the 7 Severe Respiratory Failure (SRF) centres in the UK. Two admissions were due to influenza A(unknown subtype) and one was due to non-infectious causes.

Please note that the other group includes other viral, bacterial or fungal ARI, suspected ARI, non-infection (such as asthma, primary cardiac, and trauma) and sepsis of non-respiratory origin.

Figure 46: Laboratory confirmed ECMO admissions in adults (COVID-19, influenza and non-COVID-19 confirmed) to Severe Respiratory Failure centres in the UK

SARI Watch data is provisional and subject to retrospective updates.
RSV admissions, SARI Watch

Data on hospitalisations, including ICU or HDU admissions, with respiratory syncytial virus (RSV) are shown below. RSV SARI Watch surveillance is sentinel. Please note that the SARI Watch rates for 2023 to 2024 use the latest trust catchment population. For consistency the rates have been updated back to October 2020. The population denominator reflects changes in trust reconfiguration, hospital admission activity and population estimates.

In week 8, the overall hospital admission rate for RSV remained low and decreased to 0.19 per 100,000, compared to 0.36 per 100,000 in the previous week. In children aged under 5 years hospitalisation rates were 1.31 per 100,000, which decreased compared to 2.71 per 100,000 in the previous week. In those aged 85 years and over, RSV hospitalisation rates increased to 1.70 per 100,000 from 0.00 per 100,000 in the previous week.

Figure 47. Weekly overall hospital admission rates (including ICU or HDU) of RSV positive cases per 100,000 population reported through SARI Watch sentinel surveillance, England [note 17]

[note 17] Rates are based on the number of hospitalised cases divided by the Trust catchment population, multiplied by 100,000.

RSV admission rate based on 19 NHS trusts for week 8.
Figure 48: Weekly count hospital admissions of RSV positive cases reported through SARI Watch sentinel surveillance by level of care, England
Figure 49a. Weekly hospitalisation (including ICU or HDU) admission rates by age group for RSV cases reported through SARI Watch sentinel surveillance, England - fixed y-axis [note 3]

See [note 3] as above.

Figure 49b. Weekly hospitalisation (including ICU or HDU) admission rates by age group for RSV cases reported through SARI Watch sentinel surveillance, England adjusted y-axis

SARI Watch data is provisional.
Mortality surveillance

COVID-19 deaths

For further information on COVID-19 related deaths in England please see the COVID-19 dashboard for death.

All-cause mortality assessment (England)

For further information on all-cause mortality in England please see the excess mortality within England: post-pandemic report, which uses Office for National Statistics (ONS) death registration data, all-cause mortality surveillance report, which uses the European mortality monitoring (EuroMOMO) model to identify weeks with higher than expected mortality and the ONS all-cause excess mortality report.
Respiratory virus vaccination

Influenza vaccination

Influenza vaccine uptake in GP patients

Last week, monthly data which cover vaccinations that were given between 1 September and 31 January 2024 for GP patients, frontline healthcare workers and school aged children has been published for the fourth time this season and comparator data is available for previous seasons. The monthly GP report includes ethnicity data for at-risk groups, pregnant women and those aged 65 years and over.

The last monthly GP report (all vaccinations given up to 29 February 2024) will be published on 28 March 2024.

Influenza vaccine uptake in school age children

Provisional monthly data on influenza vaccine uptake in children of school years Reception to Year 11 was published last week, showing the provisional proportion of children who received the 2023 to 2024 influenza vaccine via school, pharmacy or GP practice between 1 September and 31 January 2024.

For school aged children, this was the last publication of monthly vaccine uptake data of the season.

Influenza vaccine uptake in healthcare workers

Last week, provisional monthly data on influenza vaccine uptake in frontline healthcare workers was published, showing vaccine uptake at national, commissioning region, and Trust level, and by staff group, between 1 September and 31 January 2024.

The last monthly report (all vaccinations given up to 29 February 2024) will be published on Thursday 21 March 2024.

COVID-19 vaccine uptake in England

COVID-19 vaccine uptake in healthcare workers

Monthly data for frontline healthcare workers was published for the fourth time this autumn. This covers vaccinations that were given between 1 September and 31 January 2024 and is available under the joint flu and COVID-19 vaccine uptake report.

The last monthly report (all vaccinations given up to 29 February 2024) will be published on Thursday 21 March 2024.
International update

Global COVID-19 update

For further information on the global COVID-19 situation please see the World Health Organization (WHO) COVID-19 situation reports.

Global influenza update

For further information on the global influenza situation please see the World Health Organization (WHO) Influenza update.

Influenza in Europe

For further information on influenza in Europe please see the European Respiratory Virus Surveillance Summary weekly update.

Influenza in North America

For further information on influenza in the United States of America please see the Centre for Disease Control weekly influenza surveillance report. For further information on influenza in Canada please see the Public Health Agency weekly influenza report.

Influenza in Australia

For further information on influenza in Australia, please see the Australian Influenza Surveillance Report and Activity Updates.

Other respiratory viruses

Avian influenza and other zoonotic influenza

For further information, please see the Latest WHO update on 21 December 2023 and the Latest UKHSA avian influenza technical briefing 14 July 2023.

Middle East respiratory syndrome coronavirus (MERS-CoV)

For further information please see the WHO Disease Outbreak News Reports and the WHO publishes monthly updates.

Further information on management and guidance of possible cases is available online. The latest highlights that risk of widespread transmission of MERS-CoV remains very low.
Related links

Previous national COVID-19 reports
Previous weekly influenza reports
Annual influenza reports
COVID-19 vaccine surveillance reports
Previous COVID-19 vaccine surveillance reports
Public Health England (PHE) monitoring of the effectiveness of COVID-19 vaccination
Investigation of SARS-CoV-2 variants of concern: technical briefings
Sources of surveillance data for influenza, COVID-19 and other respiratory viruses
RCGP Virology Dashboard

UKHSA has delegated authority, on behalf of the Secretary of State, to process Patient Confidential Data under Regulation 3 The Health Service (Control of Patient Information) Regulations 2002

Regulation 3 makes provision for the processing of patient information for the recognition, control and prevention of communicable disease and other risks to public health.
About the UK Health Security Agency

UKHSA is responsible for protecting every member of every community from the impact of infectious diseases, chemical, biological, radiological and nuclear incidents and other health threats. We provide intellectual, scientific and operational leadership at national and local level, as well as on the global stage, to make the nation health secure.

The UK Health Security Agency is an executive agency, sponsored by the Department of Health and Social Care.

© Crown copyright 2024

Prepared by: Immunisation and Vaccine Preventable Diseases Division
For queries relating to this document, please contact: respdsr.enquiries@ukhsa.gov.uk

Published: 29 February 2024
Publishing reference: GOV-16264

You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit OGL. Where we have identified any third-party copyright information you will need to obtain permission from the copyright holders concerned.